QCP Capital: BTC successfully defended the $67,100 level, and ETH spot ETF may benefit after launch
According to TechFlow, QCP Capital said in a statement that BTC has successfully defended the $67,100 level for the fourth consecutive time and continued to consolidate within the range. Concerns that Mt Gox may release Bitcoin supply in October may hinder BTC, but ETH spot ETFs may benefit after their launch.
ETH bullish sentiment is strong, and a large amount of buying is observed for 4k/5k ETH call options at the end of June 2024. Traders turned to high-beta Meme coins such as Shiba Inu (SHIBA), Dogecoin (DOGE) and Pepe (PEPE), which have risen by double digits and are ranked in the top 10 in terms of holdings.
BlackRock submitted a revised S-1 form, and other issuers may follow suit, and approval may come in early July. In addition, it gave a trading suggestion that as the market consolidates within the range, waiting for the launch of the ETH spot ETF, accumulating ETH remains attractive.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
